ALLMedicine™ Alpha-mannosidosis Center
Research & Reviews 30 results
https://clinicaltrials.gov/ct2/show/NCT02998879
Oct 26th, 2021 - The Primary endpoints of the study include: Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) Detection of anti-velmanase alfa antib...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494324
PloS One; Mkaouar R, Riahi Z et. al.
Oct 7th, 2021 - Alpha-Mannosidosis (AM) is an ultra-rare storage disorder caused by a deficiency of lysosomal alpha-mannosidase encoded by the MAN2B1 gene. Clinical presentation of AM includes mental retardation, recurrent infections, hearing loss, dysmorphic fea...
https://doi.org/10.1017/cjn.2021.208
The Canadian Journal of Neurological Sciences. Le Journal... Malaquias MJ, Pinto E et. al.
Sep 7th, 2021 - Alpha-Mannosidosis: A Novel Cause of Bilateral Thalami and Dentate Nuclei Hyperintensity.|2021|Malaquias MJ,Pinto E,Oliveira J,Freixo JP,Caseiro C,|
https://doi.org/10.1097/MCD.0000000000000361
Clinical Dysmorphology; Sandal S, Razdan TB et. al.
Dec 9th, 2020 - Alpha-mannosidosis in a family: natural history with an uncommon retinal dystrophy.|2020|Sandal S,Razdan TB,Verma J,Dubey S,Ghosh A,|
https://doi.org/10.1007/s12325-020-01574-w 10.1186/1750-1172-3-21 10.1016/j.ymgmr.2019.100480 10.1186/1750-1172-8-88 10.1007/s10545-013-9622-2 10.1016/j.jval.2018.04.1684 10.1002/ajmg.a.61273 10.1016/j.ymgme.2020.04.001 10.1016/j.ymgme.2019.01.024 10.1002/jimd.12138 10.1016/j.ymgme.2018.04.003 10.1007/s10545-018-0185-0 10.1016/j.ymgme.2016.11.048 10.1007/s10545-018-0175-2 10.1016/j.ymgmr.2020.100586 10.3390/ijns4030023 10.1016/j.ymgme.2019.05.016
Advances in Therapy; Verrecchia E, Sicignano LL et. al.
Nov 25th, 2020 - Alpha-mannosidosis is a rare lysosomal storage disorder that generally presents in early childhood. It is a progressive, highly heterogeneous disease that is difficult to recognize, and a diagnosis is usually reached after referrals to multiple sp...
Clinicaltrials.gov 4 results
https://clinicaltrials.gov/ct2/show/NCT02998879
Oct 26th, 2021 - The Primary endpoints of the study include: Safety and tolerability of velmanase alfa as per Adverse events (AEs, including IRR), vital signs, laboratory parameters (hematology, biochemistry and urinanalysis) Detection of anti-velmanase alfa antib...
https://clinicaltrials.gov/ct2/show/NCT01681953
Aug 3rd, 2020 - The overall objective of this trial is to evaluate the efficacy and safety of repeated Lamazym i.v. treatment, compared with placebo, in subjects 5-35 years of age with alpha-Mannosidosis
https://clinicaltrials.gov/ct2/show/NCT01268358
Aug 3rd, 2020 - This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym. In order to avoid development of delayed hypersensitivity all pa...
https://clinicaltrials.gov/ct2/show/NCT01285700
Sep 26th, 2012 - This is a single-center, open-label, multiple-dose study of the efficacy and long-term safety of Lamazym for the treatment of patients with alpha-mannosidosis.
News 1 results
https://www.medscape.com/viewarticle/907402
Jan 9th, 2019 - In 2018, the European Medicines Agency (EMA) recommended marketing authorization for 84 new medicines, down from 92 in 2017. The 84 medicines given a thumbs up by EMA's Committee for Medicinal Products for Human Use include 42 agents with a new ac...
